IKNA ikenaoncology.com Final Profit

Corporate emblem and logo of ikenaoncology.com (IKNA)

Ikena Oncology, Inc. (IKNA) is developing a series of targeted anticancer agents, utilizing biomarker analysis to minimize risks. The company's financial profit, as shown on this GURU.Markets chart which reflects -0.03 as the current value, helps evaluate management. While the biopharmaceutical firm relies on genomic analysis and scientific expertise, it is currently seeking a buyer due to clinical failures.

IKNA (Ikena) Net Profit history from 07/04/2022 to 08/09/2025

Analytical breakdowns and data insights for company ikenaoncology.com (IKNA)

- stock value and consensus price forecast:
Market Price Ikena Oncology|IKNA - Price Target Chart
- market capitalization data:
Market Value Ikena Oncology, Inc.|IKNA - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Ikena Oncology|IKNA - Book Capitalization|Market Cap to Net Assets Ratio ikenaoncology.com|IKNA - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Ikena Oncology, Inc.|IKNA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Ikena Oncology|IKNA - Company Aggregate Debts|Debts to Book Value Ikena Oncology, Inc.|IKNA - Company Long-Term Debts|Short-Term Debt Volume Ikena Oncology|Quick Ratio ikenaoncology.com
- net income and valuation multiples indicators:
IKNA - Net Profit
Fundamental valuation:IKNA Ikena
Manufactured product of Ikena Oncology Inc.

Net income reflects the final financial result after deducting all operating expenses and taxes, allowing for an assessment of the business's actual solvency and stability. For Ikena Oncology, Inc. (IKNA), the optimization of active substance supply chains directly impacts cost minimization, which is reflected in the company's net income trends and serves as an indicator of capital management efficiency during drug development.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Net Financial Result sellaslifesciences.com|Company Net Income Actuate Therapeutics ACTU|Net Profit Citius Oncology Inc. CTOR|TuHURA - Net Profit|Company Net Income Protara Tx|Fate Therapeutics, Inc. (FATE) - Company Net Income|Company Profit WHWK|TCRX (TScan Therapeutics Inc) - Net Profit|Net Profit Champions Oncology Corp|Net Income XBIT (XBiotech Inc.)|CVM (cel-sci.com) - Final Profit|Company Net Income OS Therapies Incorporated OSTX|Radiopharm Theranostics Ltd (RADX) - Company Net Income|ARTV - Company Net Income|ANL (Adlai Nortye Ltd.) - Company Profit|VERU: Net Profit|Net Income Tempest Therapeutics Corp|Company Net Income Xilio Therapeutics Inc|Company Net Income Enochian BioSciences RENB|Company Net Income Mural Oncology plc (MURA)|Company Net Income KAPA (kairospharma.com)|Company Net Income OnKure Therapeutics OKUR|CytoMed Therapeutics Ltd (GDTC) - Company Net Income|Curis Corp - Net Profit|Annual Net Income Apollomics, Inc. (APLM)|THAR (Tharimmune) - Net Income|Company Net Income Advanced Biomed (ADVB)|Net Income GNPX|CLDI: Final Profit|Net Profit SBFM|Net Financial Result xeneticbio.com|Company Net Income Salarius Pharmaceuticals, Inc. SLRX|PPBT: Company Profit|AON - Net Profit|BeiGene Ltd (BGNE) - Net Income|CKPT (Checkpoint Therapeutics) - Net Income|ELEV - Net Financial Result|ICAD (iCAD Inc.) - Net Profit|Notable Labs Ltd (NTBL) - Net Financial Result|Company Net Income Viracta Therapeutics (VIRX)|Net Profit MorphoSys Corporation (MOR)|Company Net Income NAYA Biosciences NAYA|AAPGV: Company Profit